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Background: Women have traditionally been underrepresented in cardiovascular randomized clinical trials (CV RCT), and the reason for this 
persistent enrollment pattern is largely unknown. Our aims were i) to evaluate the extent to which women are underrepresented compared to their 
expected rates of enrollment based on population disease prevalence; and ii) to determine the degree to which female underrepresentation is 
attributed to age-recruitment biases.
Methods: We systematically reviewed CV RCT, published from January 1, 1997 to December 31, 2009 in JAMA, NEJM, and the Lancet. We extracted 
information on proportion of women enrolled and other CV RCT characteristics. The female proportion expected to be enrolled in each trial was 
estimated using Canadian population databases for each CV disease subgroup. We also examined correlation statistics between female enrollment 
and age of enrolled patients.
Results: Of the 324 CV RCT examined, the proportion of women enrollment was 33%. No significant increasing trend in female enrollment was 
observed over time (P = 0.72). Female enrollment was 29% in heart failure (HF) trials, 28% in coronary artery disease (CAD) trials, 35% in arrhythmia 
trials, and 46% in primary prevention trials (PPT). If equal enrollment between men and women was expected, one might conclude substantial 
underenrollment of women in CV RCT. However, the proportion of women expected to be enrolled based on age and gender prevalence of disease 
was much lower than half at 40% for HF trials, 32% for CAD trials, 40% for arrhthytmia trials, and 48% for PPT. A strong correlation between 
advancing age of patient enrolled and increasing female participation was observed in trials of HF (r=0.49, p=0.0002), CAD (r=0.49, p= 0.005) and 
arrhythmia (r=0.40, p=0.0001).
Conclusions: In landmark CV RCT, the extent of female underrepresentation is significantly smaller than traditionally believed when population 
disease prevalence was considered. In fact, the persistent gap in female enrollment may be an epiphenomenon of age disparity between RCT and 
clinical practice. Future efforts to increase female enrollment should include efforts to increase enrollment of older patients.
